ArticleTranslational oncology2022

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression.

Yueh-Te Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.